Widjaja Christella E, Olvera Jocelyn G, Metz Patrick J, Phan Anthony T, Savas Jeffrey N, de Bruin Gerjan, Leestemaker Yves, Berkers Celia R, de Jong Annemieke, Florea Bogdan I, Fisch Kathleen, Lopez Justine, Kim Stephanie H, Garcia Daniel A, Searles Stephen, Bui Jack D, Chang Aaron N, Yates John R, Goldrath Ananda W, Overkleeft Hermen S, Ovaa Huib, Chang John T
Department of Medicine and.
Division of Biological Sciences, UCSD, La Jolla, California, USA.
J Clin Invest. 2017 Oct 2;127(10):3609-3623. doi: 10.1172/JCI90895. Epub 2017 Aug 28.
During an immune response, CD8+ T lymphocytes can undergo asymmetric division, giving rise to daughter cells that exhibit distinct tendencies to adopt terminal effector and memory cell fates. Here we show that "pre-effector" and "pre-memory" cells resulting from the first CD8+ T cell division in vivo exhibited low and high rates of endogenous proteasome activity, respectively. Pharmacologic reduction of proteasome activity in CD8+ T cells early during differentiation resulted in acquisition of terminal effector cell characteristics, whereas enhancement of proteasome activity conferred attributes of memory lymphocytes. Transcriptomic and proteomic analyses revealed that modulating proteasome activity in CD8+ T cells affected cellular metabolism. These metabolic changes were mediated, in part, through differential expression of Myc, a transcription factor that controls glycolysis and metabolic reprogramming. Taken together, these results demonstrate that proteasome activity is an important regulator of CD8+ T cell fate and raise the possibility that increasing proteasome activity may be a useful therapeutic strategy to enhance the generation of memory lymphocytes.
在免疫反应过程中,CD8 + T淋巴细胞可进行不对称分裂,产生具有不同倾向的子细胞,分别分化为终末效应细胞和记忆细胞。我们在此表明,体内首次CD8 + T细胞分裂产生的“前效应”细胞和“前记忆”细胞分别表现出低水平和高水平的内源性蛋白酶体活性。在分化早期对CD8 + T细胞的蛋白酶体活性进行药理学降低,会导致终末效应细胞特征的获得,而蛋白酶体活性的增强则赋予记忆淋巴细胞的特性。转录组学和蛋白质组学分析表明,调节CD8 + T细胞中的蛋白酶体活性会影响细胞代谢。这些代谢变化部分是通过Myc的差异表达介导的,Myc是一种控制糖酵解和代谢重编程的转录因子。综上所述,这些结果表明蛋白酶体活性是CD8 + T细胞命运的重要调节因子,并提出增加蛋白酶体活性可能是增强记忆淋巴细胞生成的一种有用治疗策略的可能性。